Iovance Biotherapeutics Inc
IOVA
NASDAQ
Biotechnology
$6.98
USD
+0.46 (+7.06%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.98B
Volume 17.4M
Revenue
$324.97M
TTM
+34.5%
YoY
Gross Margin
48%
TTM
+45.0%
YoY
Net Income
$-289.52M
TTM
+25.7%
YoY
Operating Cash Flow
$-264.18M
TTM
+12.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 60.0 | 67.5 | 86.8 | 71.4 | 99.3 |
YoY Growth | +92.7% | +15.2% | +17.7% | +44.8% | +65.7% |
Cost of Revenue | 48.9 | 38.5 | 43.1 | 42.5 | 43.6 |
Gross Profit | 11.1 | 29.0 | 43.7 | 28.9 | 55.7 |
Selling, General & Administrative | 37.6 | 34.6 | 36.4 | 38.9 | 39.3 |
Other Operating Expenses | 0.0 | 5.1 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 124.8 | 123.9 | 117.1 | 110.0 | 107.6 |
Operating Income | -113.8 | -94.9 | -73.5 | -81.0 | -51.9 |
EBITDA | -104.4 | -81.0 | -63.5 | -72.5 | -42.4 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 4.1 | 1.2 | 1.7 | 1.3 | 3.2 |
Income Before Income Taxes | -109.7 | -93.7 | -71.7 | -79.7 | -48.7 |
Income Taxes | 2.0 | -2.4 | 0.2 | -0.7 | -1.4 |
Net Income | -111.7 | -91.3 | -71.9 | -79.0 | -47.3 |
Consolidated Net Income / Loss | -111.7 | -91.3 | -71.9 | -79.0 | -47.3 |
Net Income Attributable to Common Shareholders | -111.7 | -91.3 | -71.9 | -79.0 | -47.3 |
Basic EPS | -$0.33 | -$0.25 | -$0.18 | -$0.19 | -$0.11 |
Diluted EPS | -$0.33 | -$0.25 | -$0.18 | -$0.19 | -$0.11 |
Basic Shares Outstanding | 334.5M | 364.0M | 408.0M | 418.5M | 450.2M |
Diluted Shares Outstanding | 334.5M | 364.0M | 408.0M | 418.5M | 450.2M |